Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | opiate receptor-like 1 | Starlite/ChEMBL | References |
Homo sapiens | potassium voltage-gated channel, subfamily H (eag-related), member 2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | growth hormone secretagogue receptor type 1 | opiate receptor-like 1 | 370 aa | 349 aa | 22.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0045 | 0.028 | 0.2149 |
Schistosoma mansoni | hyperpolarization activated cyclic nucleotide-gated potassium channel | 0.0009 | 0.0013 | 0.0015 |
Toxoplasma gondii | kinesin motor domain-containing protein | 0.0175 | 0.1254 | 0.5 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0045 | 0.028 | 0.0267 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0045 | 0.028 | 0.2149 |
Schistosoma mansoni | hypothetical protein | 0.1173 | 0.8694 | 1 |
Plasmodium vivax | kinesin-5 | 0.0175 | 0.1254 | 0.5 |
Schistosoma mansoni | kinesin eg-5 | 0.0175 | 0.1254 | 0.1442 |
Giardia lamblia | Kinesin-5 | 0.0175 | 0.1254 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0013 | 0.0044 | 0.005 |
Plasmodium falciparum | kinesin-5 | 0.0175 | 0.1254 | 0.5 |
Echinococcus granulosus | voltage gated potassium channel | 0.0013 | 0.0044 | 0.0031 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0013 | 0.0044 | 0.0031 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0013 | 0.0044 | 0.0031 |
Echinococcus multilocularis | kinesin family 1 | 0.1348 | 1 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0009 | 0.0013 | 0.0015 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0049 | 0.031 | 0.0357 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0013 | 0.0044 | 0.005 |
Loa Loa (eye worm) | hypothetical protein | 0.0039 | 0.0236 | 0.1795 |
Entamoeba histolytica | kinesin, putative | 0.0175 | 0.1254 | 0.5 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0042 | 0.0258 | 1 |
Schistosoma mansoni | hyperpolarization activated cyclic nucleotide-gated potassium channel | 0.0009 | 0.0013 | 0.0015 |
Brugia malayi | Kinesin motor domain containing protein | 0.0175 | 0.1254 | 1 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0009 | 0.0013 | 0.0015 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0013 | 0.0044 | 0.0031 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0009 | 0.0013 | 0.0015 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0049 | 0.031 | 0.0357 |
Loa Loa (eye worm) | hypothetical protein | 0.0013 | 0.0044 | 0.0246 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0045 | 0.028 | 0.0267 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0009 | 0.0013 | 0.0015 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0042 | 0.0258 | 1 |
Loa Loa (eye worm) | kinesin-like protein KLP2 | 0.0175 | 0.1254 | 1 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0013 | 0.0044 | 0.0246 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 11 nM | Displacement of [125I]Tyr14-NC/OFQ from human ORL1 receptor | ChEMBL. | 19447610 |
IC50 (functional) | = 12 nM | Antagonist activity at ORL1 receptor expressed in CHO cells assessed as inhibition of NC/OFQ-stimulated [35S]GTPgammaS binding | ChEMBL. | 19447610 |
IC50 (binding) | = 2700 nM | Displacement of [35S]MK499 from human ERG expressed in HEK293 cells | ChEMBL. | 19447610 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.